FDA Clears Abbott’s New FFR Coronary Lesion Assessment Technology

March 06, 2019

The U.S. Food and Drug Administration (FDA) cleared Abbott’s Resting Full-cycle Ratio (RFR) intravascular diagnostic test to identify significant narrowing of coronary arteries to determine the need for a stent or if a patient can be treated medically.